Autonomix Medical, Inc. (AMIX)
NASDAQ:AMIX
Want to see AMIX full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Patent Grant
The new patent strengthens Autonomix's intellectual property portfolio, enhancing its competitive edge in medical device innovation and potentially expanding its market reach.
Negative Factors
Zero Revenue
Lack of revenue generation is a critical concern, indicating challenges in monetizing products and achieving sustainable growth, which could impact long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Patent Grant
The new patent strengthens Autonomix's intellectual property portfolio, enhancing its competitive edge in medical device innovation and potentially expanding its market reach.
Read all positive factors
Autonomix Medical, Inc. (AMIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.44M
Dividend YieldN/A
Average Volume (3M)456.51K
Price to Earnings (P/E)―
Beta (1Y)-0.05
Revenue GrowthN/A
EPS Growth62.20%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-3.04
Shares Outstanding11,409,344
10 Day Avg. Volume742,337
30 Day Avg. Volume456,513
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.78
Price to Sales (P/S)0.00
P/FCF Ratio-2.29
Enterprise Value/Market Cap-1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit824.25
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$2.00Price Target Upside412.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.08
Revenue Forecast (FY)N/A
Autonomix Medical, Inc. Business Overview & Revenue Model
Company Description
Autonomix Medical, Inc. is an emerging medical device company focused on developing advanced solutions for identifying and treating various disorders impacting the peripheral nervous system. At the core of its innovation is a sophisticated technol...
Autonomix Medical, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.00K | -183.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.03M | -11.05M | -15.27M | -1.99M | 0.00 |
| Net Income | -16.71M | -11.41M | -15.43M | -1.99M | -13.33M |
Balance Sheet | |||||
| Total Assets | 7.60M | 9.81M | 9.41M | 865.00K | 2.05M |
| Cash, Cash Equivalents and Short-Term Investments | 7.00M | 9.14M | 8.61M | 865.00K | 2.04M |
| Total Debt | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 |
| Total Liabilities | 1.71M | 1.71M | 1.78M | 221.00K | 93.24K |
| Stockholders Equity | 5.89M | 8.10M | 7.63M | 644.00K | 1.96M |
Cash Flow | |||||
| Free Cash Flow | -12.29M | -8.27M | -6.67M | -1.85M | -387.31K |
| Operating Cash Flow | -12.28M | -8.26M | -6.65M | -1.85M | -387.31K |
| Investing Cash Flow | -10.00K | -14.00K | -19.00K | 0.00 | 0.00 |
| Financing Cash Flow | 10.16M | 8.80M | 14.41M | 675.00K | 2.43M |
Autonomix Medical, Inc. Technical Analysis
Negative
0.39
Price Trends
0.38
Positive
0.39
Negative
0.66
Negative
Market Momentum
<0.01
Positive
48.21
Neutral
37.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMIX, the sentiment is Negative. The current price of 0.39 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.38, and below the 200-day MA of 0.66, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 37.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMIX.
Autonomix Medical, Inc. Risk Analysis
Autonomix Medical, Inc. disclosed 50 risk factors in its most recent earnings report. Autonomix Medical, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Autonomix Medical, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $4.44M | -1.66 | -228.82% | ― | ― | 62.20% | |
48 Neutral | $35.90M | -1,699.82 | -12.72% | ― | 100.82% | 42.21% | |
45 Neutral | $35.01M | -0.42 | -9999.00% | ― | -95.74% | -118.94% | |
40 Underperform | $5.99M | -0.67 | -220.42% | ― | ― | 51.71% |
* Healthcare Sector Average
AMIX
Autonomix Medical, Inc.
0.39
-0.92
-70.38%
PAVM
PAVmed
5.00
-14.15
-73.89%
MOVE
Movano
18.91
14.05
288.99%
HSCS
Heart Test Laboratories, Inc.
1.80
-1.77
-49.58%
Autonomix Medical, Inc. Corporate Events
Private Placements and Financing
Autonomix Medical Raises $5M in Private Placement
Neutral
Nov 19, 2025
On November 18, 2025, Autonomix Medical, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell pre-funded warrants and Series C Warrants in a private placement. The transaction, which closed on November 19, 2025,...
Shareholder MeetingsStock Split
Autonomix Medical Holds Annual Stockholders Meeting
Neutral
Nov 3, 2025
On October 30, 2025, Autonomix Medical, Inc. held its annual meeting of stockholders, where a quorum was achieved with 48% of shares voting. During the meeting, all director nominees were elected, and several proposals were approved, including the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―